TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05686031

Intervention type: OTHER
Intervention: No interventions were done between groups
Description: No interventions were done between groups

Intervention type: OTHER
Intervention: No interventions were done between groups
Description: No interventions were done between groups
Study: NCT02540109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tDCS (Soterix Medical, Active)
Description: Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tDCS (Soterix Medical, Sham)
Description: Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
Study: NCT00895232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort II

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort III
Study: NCT02214407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days. Hydroxyurea may be added during the first 3 cycles if WBC counts \> 30 G/L, and mandatory if WBC \> 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYDROXYUREA
Description: Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee.
Study: NCT03451266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 1,5g of IV vitamin C in 100 ml 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100 ml of IV 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum.
Study: NCT04332133

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser interference,INTRAVITREAL INJECTION
Description: sub threshold micro pulse laser for DME for group 1 and intravitreal injection of Ranibizumab for group 2

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser interference,INTRAVITREAL INJECTION
Description: sub threshold micro pulse laser for DME for group 1 and intravitreal injection of Ranibizumab for group 2
Study: NCT01330680

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coffee
Description: 40 mL dose of a decaffeinated preparation spiked with the addition of caffeine, at a dose of 3 mg/kg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Decaffeinated coffee
Description: 40 mL dose of decaffeinated coffee
Study: NCT01690585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject 1000 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chlorure 0,9 %
Study: NCT03185988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy in combination with trastuzumab for arm1
Description: Arm1: GI tumor beyond CRC, ESCC, BTC and GC\&GEJA Trastuzumab (Herceptin ®): 6 mg/kg every 3 weeks (8 mg/kg as loading dose at 1st administration), iv, d1.The first infusion is to be given over 90 minutes, and subsequent infusions are to be given over 30 minutes if the first infusion is well tolerated.Combined chemotherapy (by investigator's choice)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy in combination with trastuzumab for arm2
Description: Arm2: esophageal squamous cell carcinoma (ESCC) Trastuzumab (Herceptin ®): the same as above Combined with Irinotecan: 120 mg/m2 IV, day 1 and day 8, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy in combination with trastuzumab for arm3
Description: Arm 3: biliary tract cancer (BTC) Trastuzumab (Herceptin®): the same as above Combined chemotherapy (by investigator's choice) The combined chemotherapy of cohort 1 and 3 is Irinotecan: 120 mg/m2 IV, day 1and day 8, every 3 weeks.~OR 5-Fu: 720 mg/m2/day, continuous IV. Infusion over 5 days, every 3 weeks. OR Capecitabine(Xeloda®):1000 mg/m2 bid, d1-d14, every 3 weeks. The chemotherapy regimen is chosen at the Investigator's discretion and can be determined on an individual patient basis. Special cases should be discussed with the principal investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy in combination with trastuzumab for arm4
Description: Trastuzumab (Herceptin ®): same as above Combined with Irinotecan: 120 mg/m2 iv, day 1and day 8, every 3 weeks. OR Capecitabine(Xeloda®)1000 mg/m2 bid, d1-d14, every 3 weeks. OR Irinotecan: 120 mg/m2 iv, day 1and day 8 and Capecitabine(Xeloda®)1000 mg/m2 bid, d1-d14, every 3 weeks (by investigator's choice)
Study: NCT01504620

Intervention type: OTHER
Group type: OTHER
Intervention: Sugar infusion
Description: Infusion of glucose to achieve high blood glucose levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin infusion
Description: i.v. infusion of insulin
Study: NCT06679699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trunk control exercises combined with patient education program
Description: Patients in this group received about 45-60 minutes of trunk control exercises in lying and sitting, 5 days a week for 4 consecutive weeks. Each exercise was performed with 10-20 repetitions per session depending on the patient's ability. Trunk exercises or other activities targeting the trunk while sitting and lying, to minimize the influence of lower extremity function performed either on a stable or unstable surfaces. In addition, the experimental group provided a patient education program which focuses on the importance of trunk control and benefits of trunk control exercises during the rehabilitation process. Further, caregivers and family members were also explained about the patient education program and adherence with treatment protocol during and after the interventions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trunk control exercises
Description: Patients in this group received about 45-60 minutes of trunk control exercises in lying and sitting, 5 days a week for 4 consecutive weeks. Each exercise was performed with 10-20 repetitions per session depending on the patient's ability. Trunk exercises or other activities targeting the trunk while sitting and lying, to minimize the influence of lower extremity function performed either on a stable or unstable surfaces.
Study: NCT02714751

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Daily asynchronies information
Study: NCT02540044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ANSWER-2 decision aid
Description: ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (TAS Consumer Guide)
Description: The Arthritis Society Consumer guide pdf.
Study: NCT03072355

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elastic Band
Description: Localized muscle resistance test for shoulder

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isokinetic dynamometer
Description: Localized muscle resistance test for shoulder
Study: NCT03141658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-134
Description: Multiple dose titrations from 10 mg to 20 mg once daily for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-134
Description: Multiple dose titrations from 10 mg to 60 mg once daily for 6 days
Study: NCT04647357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: Anti-PD-L1 antibody，Maintenance therapy, The drug was administered every three weeks
Study: NCT01489137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during head fixation. And, For this allocation of dose of remifentanil the investigators use biased coin design up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 5.5ng/ml which we predict as EC90. And, step size of dose is 0.5ng/ml.
Study: NCT01771354

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix B Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03141658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple doses of placebo once daily for 6 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.23 mg/kg bolus over one minute on Screening (baseline) and Day 6

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.23 mg/kg bolus over one minute on Screening (baseline) and Day 6

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.23 mg/kg bolus over one minute on Screening (baseline) and Day 6
Study: NCT04482348

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Explanation
Description: Explanation provided to patients for more pain than expected

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Explanation
Description: Explanation provided to patients for more pain than expected

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Explanation
Description: Explanation provided to patients for more pain than expected

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Explanation
Description: Explanation provided to patients for more pain than expected

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Explanation
Description: Explanation provided to patients for more pain than expected

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Explanation
Description: Explanation provided to patients for more pain than expected

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Explanation
Description: Explanation provided to patients for more pain than expected
Study: NCT02318433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Data demonstrates that low doses of dexamethasone preserves chondrocyte viability, protects collagen, and maintains proteoglycan synthesis in cartilage subjected to injurious compression.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT01500551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib will be administered orally BID (twice daily) approximately 12 hours (±2 hours) apart, once in the morning and once in the evening, based on body weight for all subjects for all three index studies (A3921103, A3921104, and A3921165)~5 mg BID Dose Level:~Body Weight (Dose in tablet \[mg BID\] or solution \[ml BID\]) 5 - \< 7 kg (2 mg or 2 ml) 7 - \< 10 kg (2.5 mg or 2.5 ml) 10 - \<15 kg (3 mg or 3 ml) 15 - \<25 kg (3.5 mg or 3.5 ml) 25 - \<40 kg (4 mg or 4 ml) \>=40 kg (5 mg or 5 ml)~Oral solution (1 mg/mL concentration) will be used for subjects weighing \<40 kg. Oral tablets (5 mg) will be used for subjects weighing \>=40 kg; subjects who are unable to swallow tablets will have the option of taking oral solution.~Subjects will swallow study tablets whole and will not manipulate or chew tablets prior to swallowing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: For subjects rolling over from study A3921103 and actively participating in this study at the time of Protocol Amendment 6 and receiving a dosage of tofacitinib in accordance with the dosing scheme specified in Protocol Amendment 5, investigators will have the option of maintaining the subject's current dosage regimen from index study A3921103 (if the desired clinical response has been attained with no safety concern) or adjusting the dosage regimen in accordance with the dosing scheme specified in this section.
Study: NCT03374046

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apneic Oxygenation
Description: Supplemental oxygen will be provided via nasal cannula during intubation attempt
Study: NCT04472338

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood, urine, and/or tissue samples

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02115529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nabilone
Description: Nabilone (0.5 mg) or placebo given preoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: identical capsule containing placebo (single dose) given preoperatively
Study: NCT03464773

Intervention type: OTHER
Group type: OTHER
Intervention: PIUO Pathway
Description: See arm descriptions
Study: NCT02532101

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oil Palm Phenolics
Description: Palm fruit derived phenolics compound
Study: NCT03779620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound treatment of Calcified aortic valve
Description: Ultrasound treatment of calcified aortic valve causing symptomatic aortic valve stenosis in patients who are not eligible for valve replacement
Study: NCT03682744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CEA CAR-T cells
Description: Intraperitoneal delivery of anti-CEA CAR-T cells
Study: NCT04492384

Intervention type: OTHER
Intervention: non-interventional
Description: Interview on health conditions

Intervention type: OTHER
Intervention: non-interventional
Description: Interview on health conditions
Study: NCT02033941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meganatural-Az Grapeseed Extract
Description: Meganatural-Az® doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive capsules identical in appearance to the active agent with the same incremental schedule
Study: NCT01324973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eWellness
Description: A weight management program that includes computerized delivery of evidence-based education regarding diet and physical activity, and peer coaching.
Study: NCT00200239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating breakfast with portion and unportioned foods
Description: Behavioral: eating breakfast with portion and unportioned foods

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating breakfast with portion and unportioned foods
Description: Behavioral: eating breakfast with portion and unportioned foods
Study: NCT00804232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: childhood diabetes
Description: the intervention compares three different regimes for children newly diagnosed with type 1 diabetes: (1) traditional hospital based care, (2) intensive psychological support to the family, and (3) home based family psychosocial support. A further aim is to identify families were the child runs the risk of decreased metabolic control and to give those families increased support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: childhood diabetes
Description: the intervention compares three different regimes for children newly diagnosed with type 1 diabetes: (1) traditional hospital based care, (2) intensive psychological support to the family, and (3) home based family psychosocial support. A further aim is to identify families were the child runs the risk of decreased metabolic control and to give those families increased support.
Study: NCT02657343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Study: NCT04898179

Intervention type: OTHER
Intervention: Telecare Group
Description: Home-based telehealth program: telenursing and specialist teleconsultation~Telemonitoring with a new pulse oximeter and specific App~E-health platform~Videoconference

Intervention type: OTHER
Intervention: Control group
Description: Usual care
Study: NCT00037882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-Intron
Description: Once weekly injection.
Study: NCT00143845

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced intensity conditioning
Description: Busulfan and Fludarabine regimen

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid immunosuppressive taper
Description: Taper of Tacrolimus, Methotrexate and Mycophenolate Mofetil
Study: NCT02166463

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03617120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ergonomic Brace vs hard brace
Description: Visit 1:~1. Usual check-up: standing in-brace radiograph of hard brace and doctor consultation~2. Pressure measurement of participant wearing their hard brace~Visit 2:~1. Brace Questionnaire (BrQ) for hard brace; Trunk Appearance Perception Scale (TAPS)~2. 3D body scanning (before wearing the Ergonomic Brace)~3. Fitting of the Ergonomic Brace~4. Pressure measurement of participant wearing the Ergonomic Brace (instant)~5. Pressure measurement of participant wearing the Ergonomic Brace (after 2 hours)~6. 3D body scanning (after wearing the Ergonomic Brace for 2 hours)~7. Brace Questionnaire (BrQ) for the Ergonomic Brace~Visit 3:~1. Standing in-brace radiograph of the Ergonomic Brace~2. Doctor consultation
Study: NCT00089076

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03482206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated extracranial internal carotid artery ultrasound sensor
Description: The investigators' goal is to develop a wearable noninvasive, continuous, automated ultrasound sensor to accurately measure arterial blood flow volume outside of the head. Ultrasound uses sound waves to create a picture. In doing so, the investigators hope to detect CBF compromise early, preventing secondary injuries in TBI patients.
Study: NCT00337974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational DVDs
Study: NCT03731728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CBT
Description: All therapists will use a manualized Cognitive-Behavior Therapy (CBT) protocol with the same handouts and schedule developed based on the book Mind Over Mood. Group CBT will be provided to a group of maximum 10 participants. Each session will be 2 hours long and will be provided by certified therapists with special training to deliver group CBT. The structure of the session will be agenda setting, check-in, review of homework, new concepts/skills, homework assignment, and feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group exercise
Description: Participants enrolled in the group exercise plus TAU arm of the study will be wait-listed for TAU and will receive 50 minutes of scheduled and facilitated exercises three times a week for 14 weeks.
Study: NCT01134341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate Injection
Description: Intravenous (IV) push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline (0.9% sodium chloride).~10 or 15 mg/m2, depending on cohort assignment.~Dose reductions allowed for protocol-specified criteria.~Administered weekly for 3 weeks of 4-week cycle (weekly for 3 weeks with one week of rest) until criteria for discontinuation per the protocol are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexarotene Capsules
Description: 150 or 300 mg orally, depending on cohort assignment. Provided as 75 mg capsules and taken with a meal.~Dose reductions allowed for protocol-specified criteria and implemented per the Targretin® package insert.~Administered daily until criteria for study treatment discontinuation per the protocol are met.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 1 mg intramuscular injection~Administered within 10 weeks prior to start of study treatment, every 8-10 weeks throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 1-1.25 mg orally~Administered daily for at least 7 days prior to start of study treatment, throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene).
Study: NCT00143845

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic donor leukocyte infusions
Description: If the patient has GVHD overall grade 0-1 or skin grade 1 on day +100, then 5 x 107 CD3+ cells/kg recipient weight are given.
Study: NCT00951639

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cassia cinnamon
Description: 5g encapsulated ground bark administered once in experimental session

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 50 minutes exercise
Description: 50 minutes treadmill endurance exercise at 70% of the heart rate reserve (correlated to VO2max)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose Powder
Description: 5g encapsulated powder administered during placebo experimental session